Syracuse

Interleukin-6 Interleukin-10 and Vascular Endothelial Growth Factor in Metastatic Renal Cell Carcinoma: Prognostic Value of Interleukin-6--From the Groupe Français d'Immunothérapie

Archive ouverte | Negrier, S. | CCSD

Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie

Archive ouverte | Negrier, S. | CCSD

Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project

Archive ouverte | Kramar, A. | CCSD

International audience. BACKGROUND:In clinical trials, the use of intermediate time-to-event end points (TEEs) is increasingly common, yet their choice and definitions are not standardized. This limits the usefulnes...